Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Postoperative Circulating Tumor Deoxyribonucleic Acid (ctDNA) Surveillance to Guide the Treatment of Early-Stage Triple Negative Breast Cancer Patients with Residual Disease, PREDICT-RD Trial

Trial Status: approved

This phase II trial studies whether circulating tumor deoxyribonucleic acid (ctDNA) surveillance after surgery (postoperative) can be used to guide the treatment of early-stage triple negative breast cancer (TNBC) patients that have cancer cells in the breast at the time of surgery (residual disease). Every cancer cell has unique deoxyribonucleic acid (DNA). DNA from the tumor may be found in a patient's blood and this is called ctDNA. Looking for ctDNA postoperatively may help find out if the cancer has come back. If ctDNA is found, imaging tests can be used to see if the cancer has come back and spread to other parts of the body. If the cancer has not spread, patients can then be recommended to receive further treatment with datopotamab deruxtecan (DatoDXd). DatoDXd is a monoclonal antibody, called datopotamab, linked to a chemotherapy drug, called deruxtecan. Datopotamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers deruxtecan to kill them. Postoperative ctDNA surveillance may be an effective way to guide the treatment of early-stage TNBC patients with residual disease.